Quantbot Technologies LP Boosts Holdings in Qiagen (NYSE:QGEN)

Quantbot Technologies LP raised its stake in Qiagen (NYSE:QGEN) by 536.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 72,611 shares of the company’s stock after acquiring an additional 61,211 shares during the quarter. Quantbot Technologies LP’s holdings in Qiagen were worth $3,309,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in QGEN. GAMMA Investing LLC raised its holdings in shares of Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after purchasing an additional 500 shares during the period. Toronto Dominion Bank bought a new stake in shares of Qiagen in the second quarter valued at $27,000. Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after buying an additional 243 shares during the last quarter. CWM LLC grew its stake in shares of Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock worth $103,000 after acquiring an additional 269 shares during the period. Finally, Headlands Technologies LLC increased its holdings in Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock worth $113,000 after acquiring an additional 2,189 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Price Performance

Qiagen stock opened at $43.76 on Thursday. The stock has a market cap of $9.99 billion, a price-to-earnings ratio of 112.21, a PEG ratio of 3.35 and a beta of 0.41. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The business has a 50-day simple moving average of $43.32 and a 200 day simple moving average of $43.73. Qiagen has a 52 week low of $39.03 and a 52 week high of $47.44.

Analyst Ratings Changes

Several research firms have commented on QGEN. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target on the stock. in a research note on Thursday, October 17th. Finally, Robert W. Baird boosted their target price on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $50.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.